Efficacy and Safety of a Mixture of Microencapsulated Sodium Butyrate, Probiotics, and Short Chain Fructooligosaccharides in Patients with Irritable Bowel Syndrome—A Randomized, Double-Blind, Placebo-Controlled Study DOI Open Access
Anita Gąsiorowska, Marek Romanowski, Ewa Walecka‐Kapica

et al.

Journal of Clinical Medicine, Journal Year: 2024, Volume and Issue: 14(1), P. 6 - 6

Published: Dec. 24, 2024

Objective: Biotics are increasingly being used in the treatment of irritable bowel syndrome (IBS). This study aimed to assess efficacy and safety a mixture microencapsulated sodium butyrate, probiotics (Lactocaseibacillus rhamnosus DSM 26357, Lactobacillus acidophilus 32418, Bifidobacterium longum 32946, bifidum 32403, lactis 32269), short-chain fructooligosaccharides (scFOSs) IBS patients. Methods: was randomized, double-blind, placebo-controlled trial involving 120 adult participants with IBS. The primary outcome 12-week intervention improvement symptoms quality life (QOL), assessed use IBS-Adequate Relief (IBS-AR), IBS-Global Improvement Scale (IBS-GIS), IBS-Symptom Severity Score (IBS-SSS), IBS-QOL. Secondary outcomes were number type stools (assessed via Bristol Stool Form scale), patient-recorded symptoms, anthropometric parameters, levels selected inflammatory cytokines. Results: As early as at 4 weeks, there higher percentage patients biotic group reporting adequate relief (based on IBS-AR) than placebo (64.7% vs. 42.0%, respectively, p = 0.023). At 12 fewer reported ‘worsening symptoms’ IBS-GIS) (5.9% 16.0% 0.015). There no significant differences between groups IBS-QOL or IBS-SSS any secondary measures except ‘urgency defecate’ (p 0.015) week 12, which significantly lower group. safe well tolerated. Conclusions: A consisting probiotics, small amounts scFOSs is effective improving gastrointestinal

Language: Английский

Operationalizing Team Science at the Academic Cancer Center Network to Unveil the Structure and Function of the Gut Microbiome DOI Open Access
Kevin McDonnell

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(6), P. 2040 - 2040

Published: March 17, 2025

Oncologists increasingly recognize the microbiome as an important facilitator of health well a contributor to disease, including, specifically, cancer. Our knowledge etiologies, mechanisms, and modulation states that ameliorate or promote cancer continues evolve. The progressive refinement adoption “omic” technologies (genomics, transcriptomics, proteomics, metabolomics) utilization advanced computational methods accelerate this evolution. academic center network, with its immediate access extensive, multidisciplinary expertise scientific resources, has potential catalyze research. Here, we review our current understanding role gut in prevention, predisposition, response therapy. We underscore promise operationalizing network uncover structure function microbiome; highlight unique microbiome-related expert resources available at City Hope Comprehensive Cancer Center example team science achieve novel clinical discovery.

Language: Английский

Citations

0
The functions of gut microbiota-mediated bile acid metabolism in intestinal immunity DOI Creative Commons

Yanmin He,

Weike Shaoyong, Yanli Chen

et al.

Journal of Advanced Research, Journal Year: 2025, Volume and Issue: unknown

Published: May 1, 2025

Language: Английский

Citations

0
The Complex Relationship Between Gut Microbiota and Alzheimer’s Disease: A Systematic Review DOI Creative Commons

Xuan-Peng Zhou,

Lei Sun, Wenhao Liu

et al.

Ageing Research Reviews, Journal Year: 2024, Volume and Issue: unknown, P. 102637 - 102637

Published: Dec. 1, 2024

Alzheimer's disease (AD) is a progressive, degenerative disorder of the central nervous system. Despite extensive research conducted on this disorder, its precise pathogenesis remains unclear. In recent years, microbiota-gut-brain axis has attracted considerable attention within field AD. The gut microbiota communicates bidirectionally with system through gut-brain axis, and alterations in structure function can influence progression Consequently, regulating to mitigate AD emerged as novel therapeutic approach. Currently, numerous studies concentrate intrinsic relationship between paper, we summarize multifaceted role present detailed strategies targeting microbiota, including treatment Traditional Chinese Medicine (TCM), which garnered increasing years. Finally, discuss potential for modulating alleviate AD, current challenges area research, provide an outlook future directions field.

Language: Английский

Citations

2
Consumption of resistant potato starch produces changes in gut microbiota that correlate with improvements in abnormal bowel symptoms: a secondary analysis of a clinical trial DOI Creative Commons
Jason Bush, Michelle J. Alfa

BMC Nutrition, Journal Year: 2024, Volume and Issue: 10(1)

Published: Nov. 27, 2024

Studies have linked a lack of dietary fibre, including resistant starch (RS), to disease-associated changes in intestinal bacteria. Healthy people often report abnormal bowel symptoms (ABS), bloating, constipation, abdominal pain, and diarrhea, however, connections between these the gut microbiota are poorly understood. Determining correlations ABS taxonomic groups may provide predictive value for using prebiotics mitigate combination with stool microbiome testing. Post hoc analysis three-arm randomized, double-blind, placebo-controlled clinical trial evaluating effects 3.5 g 7 potato (RPS) doses or placebo was conducted. The study population (n = 70) were healthy adults aged 18–69 years old living around Guelph, ON. Participants evaluated their stools Bristol Stool Chart also recorded any daily. presence compared treatment arms at baseline within over 1- 4-week periods. Pearson correlation used identify significant relationships bacterial taxa. Abdominal belching, gas, feeling unwell reported by participants low levels baseline. Neither RPS nor had on mean scores. However, we identified positive treatment-dependent Granulicatella, Haemophilus, Lachnospira, Olsenella, Papillibacter, Turicibacter, unclassified Enterobacteriaceae, Fusobacteriaceae, Pasteurellaceae, Gammaproteobacteria. We negative Anaerotruncus, Dorea, RFN20, Victivallis, Coriobacteriaceae, Oxalobacteraceae. These after correction repeated relative abundance taxa did not change response treatment. Finally, macronutrient intake unaffected treatments. Changes can be positively negatively correlated specific microbiota, creating opportunities personalized microbiome-targeted interventions resolve ABS. registered ClinicalTrials.gov (NCT05242913) February 16, 2022.

Language: Английский

Citations

1
Oral Health and “Modern” Digestive Diseases: Pathophysiologic and Etiologic Factors DOI Creative Commons
Mihaela Rotaru, Ana-Maria Sîngeap, Alin Ciobîcă

et al.

Biomedicines, Journal Year: 2024, Volume and Issue: 12(8), P. 1854 - 1854

Published: Aug. 15, 2024

In the contemporary era of medicine, exploring complexity human body and its intricate interactions has become a central concern for health researchers. The main purpose this article is to summarize current understanding relevant pathophysiological factors such as chronic inflammation, dysbiosis (microbial imbalance), metabolic disorders, well etiological including dietary habits, lifestyle choices, obesity, syndrome, genetic predispositions, emphasize potential avenues upcoming studies their medical significance. Additionally, aims assess impact integrated treatment approaches on patient outcomes, emphasizing need interdisciplinary collaboration between gastroenterologists, dentists, other healthcare professionals develop comprehensive care plans that address both oral digestive issues simultaneously. Among branches with significant general well-being are cavity diseases, which have been subject intensive research in recent decades. context, analysis state knowledge disorders relation “modern” diseases non-alcoholic fatty liver disease (NAFLD), small intestinal bacterial overgrowth (SIBO), inflammatory bowel (IBD), irritable syndrome (IBS) becomes essential deeper interconnections health. temporal overlap or succession, whether preceding following, manifestations should be taken seriously by gastroenterologists dentists facilitate early diagnosis explain patients correlation these two systems. summary, underscores importance relationship health, advocating improve outcomes guide future research.

Language: Английский

Citations

1
Insomnia and intestinal microbiota: a narrative review DOI
Lu Liu,

Zhu Jiwei,

Jing-Lin Wu

et al.

Sleep And Breathing, Journal Year: 2024, Volume and Issue: 29(1)

Published: Nov. 26, 2024

Language: Английский

Citations

0
Efficacy and Safety of a Mixture of Microencapsulated Sodium Butyrate, Probiotics, and Short Chain Fructooligosaccharides in Patients with Irritable Bowel Syndrome—A Randomized, Double-Blind, Placebo-Controlled Study DOI Open Access
Anita Gąsiorowska, Marek Romanowski, Ewa Walecka‐Kapica

et al.

Journal of Clinical Medicine, Journal Year: 2024, Volume and Issue: 14(1), P. 6 - 6

Published: Dec. 24, 2024

Objective: Biotics are increasingly being used in the treatment of irritable bowel syndrome (IBS). This study aimed to assess efficacy and safety a mixture microencapsulated sodium butyrate, probiotics (Lactocaseibacillus rhamnosus DSM 26357, Lactobacillus acidophilus 32418, Bifidobacterium longum 32946, bifidum 32403, lactis 32269), short-chain fructooligosaccharides (scFOSs) IBS patients. Methods: was randomized, double-blind, placebo-controlled trial involving 120 adult participants with IBS. The primary outcome 12-week intervention improvement symptoms quality life (QOL), assessed use IBS-Adequate Relief (IBS-AR), IBS-Global Improvement Scale (IBS-GIS), IBS-Symptom Severity Score (IBS-SSS), IBS-QOL. Secondary outcomes were number type stools (assessed via Bristol Stool Form scale), patient-recorded symptoms, anthropometric parameters, levels selected inflammatory cytokines. Results: As early as at 4 weeks, there higher percentage patients biotic group reporting adequate relief (based on IBS-AR) than placebo (64.7% vs. 42.0%, respectively, p = 0.023). At 12 fewer reported ‘worsening symptoms’ IBS-GIS) (5.9% 16.0% 0.015). There no significant differences between groups IBS-QOL or IBS-SSS any secondary measures except ‘urgency defecate’ (p 0.015) week 12, which significantly lower group. safe well tolerated. Conclusions: A consisting probiotics, small amounts scFOSs is effective improving gastrointestinal

Language: Английский

Citations

0